Skip to main content


Clinical/Translational Cancer Immunotherapy

Section edited by James L. Gulley, MD, PhD and Douglas G. McNeel, MD, PhD

First-in-man clinical trials (prospective clinical data only); phase II/III clinical studies; immune monitoring investigations; tumor microenvironment; combination therapies; and cell therapies.

Page 1 of 4

  1. Content type: Hypothesis

    Tumor immunotherapy using gene-modified T cells has already met with considerable success in the treatment of metastatic melanoma and B cell lymphoma. With improving patient prognoses, new questions arise. In ...

    Authors: Cormac Cosgrove, Emilia R. Dellacecca, Joost H. van den Berg, John B. Haanen, Michael I. Nishimura, I. Caroline Le Poole and Hans E. N. Bergmans

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:186

    Published on:

  2. Content type: Short report

    We previously reported the results of a multicentric prospective randomized trial of chemo-refractory metastatic breast cancer patients testing the efficacy of two doses of TGFβ blockade during radiotherapy. D...

    Authors: Silvia C. Formenti, Rachael E. Hawtin, Neha Dixit, Erik Evensen, Percy Lee, Judith D. Goldberg, Xiaochun Li, Claire Vanpouille-Box, Dörthe Schaue, William H. McBride and Sandra Demaria

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:177

    Published on:

  3. Content type: Research article

    DNA vaccines against cancer held great promises due to the generation of a specific and long-lasting immune response. However, when used as a single therapy, they are not able to drive the generated immune res...

    Authors: Alessandra Lopes, Sara Feola, Sophie Ligot, Manlio Fusciello, Gaëlle Vandermeulen, Véronique Préat and Vincenzo Cerullo

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:174

    Published on:

  4. Content type: Short report

    Merkel cell carcinoma (MCC) is a rare but clinically aggressive cancer with a high mortality rate. In recent years, antibodies blocking the interactions among PD-1 and its ligands have generated durable tumor ...

    Authors: Jaclyn LoPiccolo, Megan D. Schollenberger, Sumia Dakhil, Samuel Rosner, Osama Ali, William H. Sharfman, Ann W. Silk, Shailender Bhatia and Evan J. Lipson

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:170

    Published on:

  5. Content type: Research article

    Natural killer (NK) cells are an emerging new tool for cancer immunotherapy. To develop NK cell therapeutics from peripheral blood mononuclear cells (PBMCs) of healthy donors, substantial expansion of primary ...

    Authors: Yeon Ho Choi, Eun Jin Lim, Se Wha Kim, Yong Wha Moon, Kyung Soon Park and Hee-Jung An

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:168

    Published on:

  6. Content type: Research article

    The risk of delayed autoimmunity occurring months or years after discontinuation of immunotherapy is frequently asserted in the literature. However, specific cases were rarely described until 2018, when a wave...

    Authors: Marcus A. Couey, R. Bryan Bell, Ashish A. Patel, Meghan C. Romba, Marka R. Crittenden, Brendan D. Curti, Walter J. Urba and Rom S. Leidner

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:165

    Published on:

  7. Content type: Research article

    The oncolytic virus, coxsackievirus A21 (CVA21), has shown promise as a single agent in several clinical trials and is now being tested in combination with immune checkpoint blockade. Combination therapies off...

    Authors: Louise M. E. Müller, Matthew Holmes, Joanne L. Michael, Gina B. Scott, Emma J. West, Karen J. Scott, Christopher Parrish, Kathryn Hall, Sina Stäble, Victoria A. Jennings, Matthew Cullen, Stewart McConnell, Catherine Langton, Emma L. Tidswell, Darren Shafren, Adel Samson…

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:164

    Published on:

  8. Content type: Research article

    Cancer vaccines require adjuvants to induce effective immune responses; however, there is no consensus on optimal adjuvants. We hypothesized that toll-like receptor (TLR)3 agonist polyICLC or TLR4 agonist lipo...

    Authors: Marit M. Melssen, Gina R. Petroni, Kimberly A. Chianese-Bullock, Nolan A. Wages, William W. Grosh, Nikole Varhegyi, Mark E. Smolkin, Kelly T. Smith, Nadejda V. Galeassi, Donna H. Deacon, Elizabeth M. Gaughan and Craig L. Slingluff Jr

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:163

    Published on:

  9. Content type: Research article

    Melanoma is a very aggressive skin tumor that can be cured when diagnosed and treated in its early stages. However, at the time of identification, the tumor is frequently in a metastatic stage. Intensive resea...

    Authors: Lise Pasquet, Elisabeth Bellard, Sophie Chabot, Bostjan Markelc, Marie-Pierre Rols, Justin Teissie and Muriel Golzio

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:161

    Published on:

  10. Content type: Research article

    Efficient identification of neoantigen-specific T-cell responses in epithelial ovarian cancer (EOC) remains a challenge. Existing investigations of spontaneous T-cell response to tumor neoepitope in EOC have t...

    Authors: Song Liu, Junko Matsuzaki, Lei Wei, Takemasa Tsuji, Sebastiano Battaglia, Qiang Hu, Eduardo Cortes, Laiping Wong, Li Yan, Mark Long, Anthony Miliotto, Nicholas W. Bateman, Shashikant B. Lele, Thinle Chodon, Richard C. Koya, Song Yao…

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:156

    Published on:

  11. Content type: Research article

    Although accumulated evidence provides a strong scientific premise for using immune profiles to predict survival in patients with cancer, a universal immune profile across tumor types is still lacking, and how...

    Authors: Qingnan Zhao, Jiemiao Hu, Abhisek Mitra, Jeffry Cutrera, Wendong Zhang, Zhongting Zhang, Jun Yan, Xueqing Xia, Kris Michael Mahadeo, John Andrew Livingston, Richard Gorlick and Shulin Li

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:154

    Published on:

  12. Content type: Research article

    While significant strides in the treatment of metastatic bladder cancer have been made with immune checkpoint inhibitors, the treatment of carcinoma in situ and non-muscle invasive, non-metastatic (superficial...

    Authors: Y. Maurice Morillon II, Zhen Su, Jeffrey Schlom and John W. Greiner

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:150

    Published on:

  13. Content type: Research article

    Pet dogs spontaneously develop lymphoma. An anthracycline-based multidrug chemotherapy regimen represents the treatment cornerstone; however, cure is rarely achieved. We have been treating dogs with B-cell lym...

    Authors: Laura Marconato, Luca Aresu, Damiano Stefanello, Stefano Comazzi, Valeria Martini, Roberta Ferrari, Fulvio Riondato, Nicole Rouquet, Patrick Frayssinet and Silvia Sabattini

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:146

    Published on:

  14. Content type: Short report

    Talimogene laherparepvec is an oncolytic immunotherapy approved in the US, Europe, Australia and Switzerland. We report the final planned analysis of OPTiM, a randomized open-label phase III trial in patients ...

    Authors: Robert H. I. Andtbacka, Frances Collichio, Kevin J. Harrington, Mark R. Middleton, Gerald Downey, Katarina Ӧhrling and Howard L. Kaufman

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:145

    Published on:

  15. Content type: Research article

    D2C7-IT is a novel immunotoxin (IT) targeting wild-type epidermal growth factor receptor (EGFRwt) and mutant EGFR variant III (EGFRvIII) proteins in glioblastoma. In addition to inherent tumoricidal activity, ...

    Authors: Vidyalakshmi Chandramohan, Xuhui Bao, Xin Yu, Scott Parker, Charlotte McDowall, Yen-Rei Yu, Patrick Healy, Annick Desjardins, Michael D. Gunn, Matthias Gromeier, Smita K. Nair, Ira H. Pastan and Darell D. Bigner

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:142

    Published on:

  16. Content type: Research article

    The tumor immune microenvironment has become the focus of research in clear cell renal cell carcinoma (ccRCC) due to its important role in immune surveillance post nephrectomy. This study investigates the corr...

    Authors: Pooja Ghatalia, Jennifer Gordetsky, Fengshen Kuo, Essel Dulaimi, Kathy Q. Cai, Karthik Devarajan, Sejong Bae, Gurudatta Naik, Timothy A. Chan, Robert Uzzo, A. Ari Hakimi, Guru Sonpavde and Elizabeth Plimack

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:139

    Published on:

  17. Content type: Research article

    Human natural killer (NK) cell lines serve as an attractive source for adoptive immunotherapy, but NK-92 remains the only cell line being assessed in the clinic. Here, we established a novel NK cell line, NK10...

    Authors: Hyun Gul Yang, Moon Cheol Kang, Tae Yoon Kim, Injung Hwang, Hyun Tak Jin, Young Chul Sung, Ki-Seong Eom and Sae Won Kim

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:138

    Published on:

  18. Content type: Research article

    ONC201 is a small molecule antagonist of DRD2, a G protein-coupled receptor overexpressed in several malignancies, that has prolonged antitumor efficacy and immunomodulatory properties in preclinical models. T...

    Authors: Mark N. Stein, Jyoti Malhotra, Rohinton S. Tarapore, Usha Malhotra, Ann W. Silk, Nancy Chan, Lorna Rodriguez, Joseph Aisner, Robert D. Aiken, Tina Mayer, Bruce G. Haffty, Jenna H. Newman, Salvatore M. Aspromonte, Praveen K. Bommareddy, Ricardo Estupinian, Charles B. Chesson…

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:136

    Published on:

  19. Content type: Research article

    Immune checkpoint inhibitors (ICI) produce durable antitumor responses but provoke autoimmune toxicities, including uncommon but potentially devastating neurologic toxicities. The clinical features, including ...

    Authors: Douglas B. Johnson, Ali Manouchehri, Alexandra M. Haugh, Henry T. Quach, Justin M. Balko, Benedicte Lebrun-Vignes, Andrew Mammen, Javid J. Moslehi and Joe-Elie Salem

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:134

    Published on:

  20. Content type: Research article

    Immune regulated pathways influence both breast cancer (BrC) development and response to (neo)adjuvant chemotherapy. The sentinel lymph node (SLN), as the first metastatic site, is also the first site where Br...

    Authors: Kim M. van Pul, Ronald J.C.L.M. Vuylsteke, Rieneke van de Ven, Elisabeth A. te Velde, Emiel J. Th. Rutgers, Petrousjka M. van den Tol, Hein B.A.C. Stockmann and Tanja D. de Gruijl

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:133

    Published on:

  21. Content type: Research article

    Immune checkpoint inhibitors are not effective for pancreatic ductal adenocarcinoma (PDAC) as single agents. Vaccine therapy may sensitize PDACs to checkpoint inhibitor treatments. Annexin A2 (ANXA2) is a pro-...

    Authors: Victoria M. Kim, Alex B. Blair, Peter Lauer, Kelly Foley, Xu Che, Kevin Soares, Tao Xia, Stephen T. Muth, Jennifer Kleponis, Todd D. Armstrong, Christopher L. Wolfgang, Elizabeth M. Jaffee, Dirk Brockstedt and Lei Zheng

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:132

    Published on:

  22. Content type: Research article

    The immunogenomic changes triggered by concurrent chemoradiation therapy (CCRT), a standard neoadjuvant treatment for locally advanced esophageal squamous cell carcinoma (ESCC), are unknown. We aimed to analyz...

    Authors: Sehhoon Park, Je-Gun Joung, Yang Won Min, Jae-Yong Nam, Daeun Ryu, Dongryul Oh, Woong-Yang Park, Se-Hoon Lee, Yoon La Choi, Jin Seok Ahn, Myung-Ju Ahn, Keunchil Park and Jong-Mu Sun

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:128

    Published on:

  23. Content type: Research article

    Recurrent respiratory papillomatosis (RRP) is a human papillomavirus (HPV)-driven disorder that causes substantial morbidity and can lead to fatal distal airway obstruction and post-obstructive pneumonias. Pat...

    Authors: Clint T. Allen, Sunmin Lee, Scott M. Norberg, Damian Kovalovsky, Hong Ye, Paul E. Clavijo, Siwen Hu-Lieskovan, Richard Schlegel, Jeffrey Schlom, Julius Strauss, James L. Gulley, Jane Trepel and Christian S. Hinrichs

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:119

    Published on:

  24. Content type: Research article

    Immune checkpoint inhibitors (ICIs) represent a promising novel class of cancer therapy, but immune-mediated adverse events can complicate ICI treatment. Acute cholecystitis in patients receiving ICI therapy h...

    Authors: Hamzah Abu-Sbeih, Cynthia Nguyen Tran, Phillip S. Ge, Manoop S. Bhutani, Mazen Alasadi, Aung Naing, Amir A. Jazaeri and Yinghong Wang

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:118

    Published on:

  25. Content type: Short report

    Immune checkpoint inhibitor (ICI) use in clinical practice has unravelled a spectrum of immune-related adverse events (irAEs) due to immune system hyper-activation. ICI-related haemophagocytic lymphohistiocyto...

    Authors: Roberta Noseda, Raffaela Bertoli, Laura Müller and Alessandro Ceschi

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:117

    Published on:

  26. Content type: Research article

    Poly I:C is a powerful immune adjuvant as a result of its agonist activities on TLR-3, MDA5 and RIG-I. BO-112 is a nanoplexed formulation of Poly I:C complexed with polyethylenimine that causes tumor cell apop...

    Authors: M. Angela Aznar, Lourdes Planelles, Mercedes Perez-Olivares, Carmen Molina, Saray Garasa, Iñaki Etxeberría, Guiomar Perez, Inmaculada Rodriguez, Elixabet Bolaños, Pedro Lopez-Casas, Maria E. Rodriguez-Ruiz, Jose L. Perez-Gracia, Ivan Marquez-Rodas, Alvaro Teijeira, Marisol Quintero and Ignacio Melero

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:116

    Published on:

  27. Content type: Research article

    Cancer vaccines are designed to promote systemic antitumor immunity and tumor eradication. Cancer vaccination may be more efficacious in combination with additional interventions that may build on or amplify t...

    Authors: Lisa H. Butterfield, Lazar Vujanovic, Patricia M. Santos, Deena M. Maurer, Andrea Gambotto, Joel Lohr, Chunlei Li, Jacob Waldman, Uma Chandran, Yan Lin, Huang Lin, Hussein A. Tawbi, Ahmad A. Tarhini and John M. Kirkwood

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:113

    Published on:

  28. Content type: Research article

    The colorectal cancer antigen GUCY2C exhibits unique split tolerance, evoking antigen-specific CD8+, but not CD4+, T-cell responses that deliver anti-tumor immunity without autoimmunity in mice. Here, the cancer ...

    Authors: Adam E. Snook, Trevor R. Baybutt, Bo Xiang, Tara S. Abraham, John C. Flickinger Jr, Terry Hyslop, Tingting Zhan, Walter K. Kraft, Takami Sato and Scott A. Waldman

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:104

    Published on:

  29. Content type: Research article

    Checkpoint inhibitors (CPIs) have revolutionized the treatment of cancer, but their use remains limited by off-target inflammatory and immune-related adverse events. Solid organ transplantation (SOT) recipient...

    Authors: Noha Abdel-Wahab, Houssein Safa, Ala Abudayyeh, Daniel H. Johnson, Van Anh Trinh, Chrystia M. Zobniw, Heather Lin, Michael K. Wong, Maen Abdelrahim, A. Osama Gaber, Maria E. Suarez-Almazor and Adi Diab

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:106

    Published on:

    The Correction to this article has been published in Journal for ImmunoTherapy of Cancer 2019 7:158

  30. Content type: Research article

    The T cell bispecific antibody cibisatamab (CEA-TCB) binds Carcino-Embryonic Antigen (CEA) on cancer cells and CD3 on T cells, which triggers T cell killing of cancer cell lines expressing moderate to high lev...

    Authors: Reyes Gonzalez-Exposito, Maria Semiannikova, Beatrice Griffiths, Khurum Khan, Louise J. Barber, Andrew Woolston, Georgia Spain, Katharina von Loga, Ben Challoner, Radhika Patel, Michael Ranes, Amanda Swain, Janet Thomas, Annette Bryant, Claire Saffery, Nicos Fotiadis…

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:101

    Published on:

  31. Content type: Research article

    The CTLA-4 blocking antibody ipilimumab has demonstrated substantial and durable effects in patients with melanoma. While CTLA-4 therapy, both as monotherapy and in combination with PD-1 targeting therapies, h...

    Authors: Anne Månsson Kvarnhammar, Niina Veitonmäki, Karin Hägerbrand, Anna Dahlman, Karin Enell Smith, Sara Fritzell, Laura von Schantz, Mia Thagesson, Doreen Werchau, Kristine Smedenfors, Maria Johansson, Anna Rosén, Ida Åberg, Magnus Winnerstam, Eva Nyblom, Karin Barchan…

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:103

    Published on:

  32. Content type: Research article

    To investigate the efficacy and safety of concurrent stereotactic radiosurgery (SRS) and ipilimumab or nivolumab in patients with untreated melanoma brain metastases.

    Authors: Giuseppe Minniti, Dimitri Anzellini, Chiara Reverberi, Gian Carlo Antonini Cappellini, Luca Marchetti, Federico Bianciardi, Alessandro Bozzao, Mattia Osti, Pier Carlo Gentile and Vincenzo Esposito

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:102

    Published on:

  33. Content type: Research article

    How the immune microenvironment changes during neoadjuvant chemotherapy of primary breast cancer is not well understood.

    Authors: Xiaotong Li, Sarah Warren, Vasiliki Pelekanou, Vikram Wali, Alessandra Cesano, Mingdong Liu, Patrick Danaher, Nathane Elliott, Zeina A. Nahleh, Daniel F. Hayes, Gabriel N. Hortobagyi, William E. Barlow, Christos Hatzis and Lajos Pusztai

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:88

    Published on:

  34. Content type: Research article

    The Italian Renal Cell Cancer Early Access Program was an expanded access program that allowed access to nivolumab, for patients (pts) with metastatic renal cell carcinoma (mRCC) prior to regulatory approval.

    Authors: Elena Verzoni, Giacomo Cartenì, Enrico Cortesi, Diana Giannarelli, Andrea De Giglio, Roberto Sabbatini, Sebastiano Buti, Sabrina Rossetti, Francesco Cognetti, Francesca Rastelli, Alberto Sobrero, Daniele Turci, Cora N. Sternberg, Camillo Porta, Federico Cappuzzo, Giampaolo Tortora…

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:99

    Published on:

  35. Content type: Commentary

    Two phase III clinical trials (CheckMate 141 and KEYNOTE 040) have independently demonstrated that overall survival (OS) in recurrent and/or metastatic head and neck squamous cell carcinoma (R/M HNSCC) patient...

    Authors: Sara I. Pai, Sandrine Faivre, Lisa Licitra, Jean-Pascal Machiels, Jan B. Vermorken, Paolo Bruzzi, Viktor Gruenwald, Raul E. Giglio, C. René Leemans, Tanguy Y. Seiwert and Denis Soulieres

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:96

    Published on:

  36. Content type: Research article

    Current treatment guidelines for immune-mediated colitis (IMC) recommend 4 to 6 weeks of steroids as first-line therapy, followed by selective immunosuppressive therapy (SIT) (infliximab or vedolizumab) in pat...

    Authors: Hamzah Abu-Sbeih, Faisal S. Ali, Xuemei Wang, Niharika Mallepally, Ellie Chen, Mehmet Altan, Robert S. Bresalier, Aline Charabaty, Ramona Dadu, Amir Jazaeri, Bret Lashner and Yinghong Wang

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:93

    Published on:

  37. Content type: Research article

    A male gender driven obesity paradox (improved survival for overweight/obese patients compared to normal weight) was recently shown in melanoma in the context of checkpoint inhibition (anti-PD-1/anti-CTLA4 mon...

    Authors: Girish S. Naik, Sushrut S. Waikar, Alistair E. W. Johnson, Elizabeth I. Buchbinder, Rizwan Haq, F. Stephen Hodi, Jonathan D. Schoenfeld and Patrick A. Ott

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:89

    Published on:

  38. Content type: Research article

    Prognostic scoring systems are used to estimate the risk of mortality from metastatic renal cell carcinoma (mRCC). Outcomes from different therapies may vary within each risk group. These survival algorithms h...

    Authors: M. Fishman, J. P. Dutcher, J. I. Clark, A. Alva, G. P. Miletello, B. Curti, Neeraj Agarwal, R. Hauke, K. M. Mahoney, H. Moon, J. Treisman, S. S. Tykodi, G. Daniels, M. A. Morse, M. K. K. Wong, H. Kaufman…

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:84

    Published on:

  39. Content type: Short report

    Herein, we describe the use of systemic immunotherapy for both locally advanced and metastatic conjunctival melanoma. Current treatments for advanced conjunctival melanoma typically result in poor local contro...

    Authors: Paul T. Finger and Anna C. Pavlick

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:83

    Published on:

  40. Content type: Research article

    Immunotherapy targeting PD-1/PD-L1 fails to induce clinical responses in most patients with solid cancers. N-803, formerly ALT-803, is an IL-15 superagonist mutant and dimeric IL-15RαSushi-Fc fusion protein co...

    Authors: Karin M. Knudson, Kristin C. Hicks, Sarah Alter, Jeffrey Schlom and Sofia R. Gameiro

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:82

    Published on:

  41. Content type: Short report

    Consolidation therapies for children with intermediate- or high-risk acute myeloid leukemia (AML) are urgently needed to achieve higher cure rates while limiting therapy-related toxicities. We determined if ad...

    Authors: Rosa Nguyen, Huiyun Wu, Stanley Pounds, Hiroto Inaba, Raul C. Ribeiro, David Cullins, Barbara Rooney, Teresa Bell, Norman J. Lacayo, Kenneth Heym, Barbara Degar, Deborah Schiff, William E. Janssen, Brandon Triplett, Ching-Hon Pui, Wing Leung…

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:81

    Published on:

  42. Content type: Research article

    Epacadostat is a potent inhibitor of the immunosuppressive indoleamine 2,3-dioxygenase 1 (IDO1) enzyme. We present phase 1 results from a phase 1/2 clinical study of epacadostat in combination with ipilimumab,...

    Authors: Geoffrey T. Gibney, Omid Hamid, Jose Lutzky, Anthony J. Olszanski, Tara C. Mitchell, Thomas F. Gajewski, Bartosz Chmielowski, Brent A. Hanks, Yufan Zhao, Robert C. Newton, Janet Maleski, Lance Leopold and Jeffrey S. Weber

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:80

    Published on:

  43. Content type: Research article

    Despite the high prevalence of epidermal growth factor receptor (EGFR) overexpression in head and neck squamous cell carcinomas (HNSCCs), incorporation of the EGFR inhibitor cetuximab into the clinical managem...

    Authors: Madelyn Espinosa-Cotton, Samuel N. Rodman III, Kathleen A. Ross, Isaac J. Jensen, Kenley Sangodeyi-Miller, Ayana J. McLaren, Rachel A. Dahl, Katherine N. Gibson-Corley, Adam T. Koch, Yang-Xin Fu, Vladimir P. Badovinac, Douglas Laux, Balaji Narasimhan and Andrean L. Simons

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:79

    Published on:

  44. Content type: Research article

    Aberrant expression of the RON receptor tyrosine kinase is a pathogenic feature and a validated drug target in various types of cancers. Currently, therapeutic antibodies targeting RON for cancer therapy are u...

    Authors: Hang-Ping Yao, Liang Feng, Sreedhar Reddy Suthe, Ling-Hui Chen, Tian-Hao Weng, Chen-Yu Hu, Eun Sung Jun, Zhi-Gang Wu, Wei-Lin Wang, Song Cheol Kim, Xiang-Min Tong and Ming-Hai Wang

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:75

    Published on:

    The Correction to this article has been published in Journal for ImmunoTherapy of Cancer 2019 7:94

  45. Content type: Research article

    Immunotherapies still fail to benefit colorectal cancer (CRC) patients. Relevant functional assays aimed at studying these failures and the efficacy of cancer immunotherapy in human are scarce. 3D tumor cultur...

    Authors: Tristan Courau, Julie Bonnereau, Justine Chicoteau, Hugo Bottois, Romain Remark, Laura Assante Miranda, Antoine Toubert, Mathieu Blery, Thomas Aparicio, Matthieu Allez and Lionel Le Bourhis

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:74

    Published on:

  46. Content type: Research article

    γ9δ2T cells, which express Vγ9 and Vδ2 chains of the T cell receptor (TCR), mediate cancer immune surveillance by sensing early metabolic changes in malignant leukemic blast and not their healthy hematopoietic...

    Authors: Inez Johanna, Trudy Straetemans, Sabine Heijhuurs, Tineke Aarts-Riemens, Håkan Norell, Laura Bongiovanni, Alain de Bruin, Zsolt Sebestyen and Jürgen Kuball

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:69

    Published on:

  47. Content type: Research article

    Dendritic cells (DCs) are professional antigen presenting cells (APCs), which can activate antigen-specific CD8+ T cell immunity, resulting in tumor clearance. Immature DCs are usually stimulated by various ad...

    Authors: Hyun Jin Park, Gun-Young Jang, Young Seob Kim, Jung Hwa Park, Sung Eun Lee, Manh-Cuong Vo, Je-Jung Lee, Hee Dong Han, In Duk Jung, Tae Heung Kang and Yeong-Min Park

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:60

    Published on:

  48. Content type: Research article

    Systemic and local immune suppression plays a significant role in glioma progression. Glioma microenvironment contains both brain-resident microglial cells (MG) and bone marrow-derived macrophages (BMDM), but ...

    Authors: Laura Pinton, Elena Masetto, Marina Vettore, Samantha Solito, Sara Magri, Marta D’Andolfi, Paola Del Bianco, Giovanna Lollo, Jean-Pierre Benoit, Hideho Okada, Aaron Diaz, Alessandro Della Puppa and Susanna Mandruzzato

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:58

    Published on:

  49. Content type: Research article

    Recent evidence suggested a potential correlation between overweight and the efficacy of immune checkpoint inhibitors (ICIs) in cancer patients.

    Authors: Alessio Cortellini, Melissa Bersanelli, Sebastiano Buti, Katia Cannita, Daniele Santini, Fabiana Perrone, Raffaele Giusti, Marcello Tiseo, Maria Michiara, Pietro Di Marino, Nicola Tinari, Michele De Tursi, Federica Zoratto, Enzo Veltri, Riccardo Marconcini, Francesco Malorgio…

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:57

    Published on:

  50. Content type: Research article

    Influenza vaccination (FV) is recommended for patients with cancer. Recent data suggested that the administration of the FV was associated with an increase in immune-related adverse events (irAEs) among patien...

    Authors: Magid Awadalla, Doll Lauren Alexandra Golden, Syed S. Mahmood, Raza M. Alvi, Nathaniel D. Mercaldo, Malek Z. O. Hassan, Dahlia Banerji, Adam Rokicki, Connor Mulligan, Sean P. T. Murphy, Maeve Jones-O’Connor, Justine V. Cohen, Lucie M. Heinzerling, Merna Armanious, Ryan J. Sullivan, Rongras Damrongwatanasuk…

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:53

    Published on:

Annual Journal Metrics